Munger Mode rating: 4 out of 5 — Buy. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Price used: about $246 per share. This is the most recent quote I could find, shown on an earnings-tracking page next to a post-earnings high of $248.60. The Q1 FY27 results came out after the close on October 29. I could not confirm the exact October 30 close, so treat $246 as approximate. For scale, the accelerated share repurchase (ASR) was priced off a $230.87 close on September 2. At $246 the market capitalization is about $34.6 billion on 140.66 million shares. ResMed has about $410 million of debt against $1.01 billion of cash, so net cash is about $0.6 billion and enterprise value is about $34.0 billion. We like this business. ResMed sells the machines and masks that treat obstructive sleep apnea. Patients wear the masks every night and replace them on a schedule, and doctors and insurers know the brand.
Recent filings analysed: 8-K (2026-11-19), 10-Q (2026-10-30), 8-K (2026-10-29), DEF 14A (2026-10-01).
Stock screener · Superinvestor 13F holdings · Analyst sentiment